1Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy, 2000,20:417-428.
2Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-aquired pneumonia.Diagnosis,assessment of severity, antimicrobial therapy, and provention. Am J Respir Crit Care Med, 2001,163:1730-1754.
3Niederman MS. Treatment of respiratory in fections with quinolones. In: An drole V, editor, The quinolones, 2nd edition. San Diego. CA: McGraw-Hill,1998.229-250.
4Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther, 2000, 22:798-817.
5Zuckerman JM, Kaye KM. The newer macrolides. Azithromycin and clarithromycin. Infect Dis Clin North Am,1995,9:713-745.
7Felmingham D,Grüneberg & Alexander Project Group. Alexander Project in Europe: Decreased Susceptibility of Isolates of Stretococcus pneumoniae to Macrolides During the Perid 1992-2000. 12th ECCMID, Milan,2002. 1113.
8Jacobs MR, Appelbaum & Alexander Project Group. Antimicrobial activity of several oral β-lactams, macrolides and cotrimoxazole against streptococcus pneumoniae from Japen, Singapore, Hong Kong: Alexander Project 2000. 10th Internatioal Alexander Project Congress on Infectious Disease, Singapore,2002. 138.
10Heffelfinger JD, Dowell SF, Jorgensen JH,et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med, 2000,160:1399-1408.
